Cell harvesting systems are medical devices used in repairing damaged tissues or for transplantation purposes using stem cells. Stem cells are collected using three major methods – bone marrow, umbilical cord blood, and peripheral blood. The potency of these cells is tested by their ability to grow tissues or via clonogenic assays. Major applications of cell harvesting systems include adipose tissue, bone marrow, peripheral blood, umbilical cord, and others.
Stem cell research has attracted the interest of biopharmaceutical companies due to their latent potential in preventing cancer. This is evident by the investment of USD 1.49 billion by National Institutes of Health. In addition, rapid development in regenerative medicine and high demand for autologous stem cell transplantation for treating blood-related disorders has elicited interest in cell harvesting procedures.
Rapid Collection of Stem Cells
The peripheral blood segment is anticipated to be the dominant application over the forecast period (from 2018 to 2025) owing to usage of peripheral blood in stem cell transplants and stem cell research. Faster patient recovery and high safety levels associated with the procedure have also led to its increased adoption. According to a study by the American Society of Hematology in 2016, Terumo Corporation introduced a new system, Spectra Optia, for collecting stem cells via apheresis. The system was successful in collecting a higher amount of white blood cells using continuous mononuclear cell collection (CMNC) as opposed to its previous version.
The adipose segment is expected to exhibit a rapid growth from 2018 to 2025 due to their high usage in regenerative medicine. The advantage of easily harvesting Adipose Stem Cells (ASCs) and its potential in stem cell therapies can propel segment growth. According to a report in the International Journal of Stem Cells in 2015, ASCs were successful in regenerating tissues in animal models.
Market Outlook
The global cell harvesting system market is expected to reach at USD 10.17 billion by 2025, according to a report by Grand View Research, Inc. High prevalence of blood cancer, blood-related disorders, and increasing government expenditure on healthcare are anticipated to augur market growth in the coming years.
Rise in usage of methods, such as autologous stem cell transplantation and stem cell banking, are projected to propel market growth. Key market players include Terumo Corporation; PerkinElmer, Inc.; Bertin Technologies; and Avita Medical.
Read more @
No comments:
Post a Comment